Monday, June 11, 2007

Myriad Genetics (MYGN) Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's Conference

Current Flurizan™ Phase 3 Study Design May Demonstrate Disease Modification

Read the entire release at The Alzheimer's Reading Room






Posted by at 1 comment:
Subscribe to: Posts (Atom)